# Peptide Division — Growth Hormone Axis Research Peptides > Peptide Division is a reference digest for Growth Hormone Axis research peptides — ipamorelin, CJC-1295, and sermorelin — framed by the GHRP-vs-GHRH distinction. Published science, not sales. An independent literature digest on ipamorelin, CJC-1295, and sermorelin — what each one does at the receptor, how the human evidence actually holds up, and where the record runs thin. ## The short version Peptide Division is a reading desk, not a store. It collects what the published literature actually says about three peptides that occupy the same corner of endocrinology: the growth hormone axis. A *peptide* is a short chain of amino acids — the same building blocks as proteins, only far smaller. These three work by nudging the pituitary gland to release the body's own growth hormone rather than supplying it directly. All three were studied because the GH/IGF-1 axis touches a wide range of physiology: body composition, bone density, muscle, recovery, metabolism. But the clinical record is thinner than the pharmacology is interesting. This desk reports what each compound was tested on, in which species, and with what result — then flags plainly where the evidence stops. None of these peptides is an approved human medicine. This site does not sell anything and does not give medical advice. ## What are research peptides? Proteins in your body — a receptor, an enzyme, a signaling hormone — are long amino-acid chains folded into a shape. A *peptide* is a much shorter chain of the same units, sometimes only a handful of links long. Because small peptides are specific enough to fit particular receptors, they can act like precise signals: activating a pathway in the pituitary, triggering a hormone release, or mimicking a naturally occurring fragment. A *research peptide* is one that has been synthesized and studied in the laboratory — in cell cultures, in animals, sometimes in small early human studies — but has **not** been approved as a medicine by any regulator. Sellers describe these compounds as being for laboratory research use only. That framing matters: it means human dosing, long-term safety, and real-world effectiveness are generally unestablished. Whenever this desk reports a number, it reports it as the study did — "studied at X dose in rats" — and never as a recommendation for humans. ## How these three fit into GH-axis research The three peptides on this desk approach the same target — pituitary growth hormone release — through two different receptor systems, which is why they sit together as the "GHRP vs GHRH" pair. - [**Ipamorelin**](/ipamorelin) is the lead. It is a selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R1a) — a GHRP mechanism — that triggers a discrete GH pulse while leaving cortisol and prolactin essentially unmoved [6]. Its human record consists of one pharmacokinetics study and one Phase 2 trial that missed its primary endpoint [3][4]. - [**CJC-1295**](/cjc-1295) works from the other side: it is a GHRH analog that activates the GHRH receptor on pituitary somatotrophs, raising GH and IGF-1 for days from a single dose [11]. Human data are limited to two early pharmacology publications with no completed efficacy trial [11][12]. - [**Sermorelin**](/sermorelin) is the simplest GHRH analog — the first 29 amino acids of the natural hormone — once FDA-approved as Geref for children with growth hormone deficiency, withdrawn commercially in 2008, and now available through compounding pharmacies as a Category 1 bulk substance [15]. Its regulatory history is among the most frequently misstated stories in this space. Together they illustrate how two distinct receptor classes — GHS-R1a and GHRH-R — converge on the same downstream signal, and why combining them is pharmacologically rational even though the stack itself has no controlled human trial behind it. Use the directory to read each one, or [compare these peptides](/compare) side by side. ## How this desk reads the literature Peptide Division is a cross-referenced literature digest. The organizing principle is evidence quality: not whether a mechanism is interesting, but whether a controlled study in a relevant species has actually tested it. Where the record is animal-only, single-lab, or derived from a short perioperative window rather than long-term use, the pages say so plainly. Where a popular claim in circulation has no peer-reviewed anchor — anti-aging, fat loss, muscle gain — this desk names the absence of evidence rather than filling it with plausible reasoning. Each compound page cites numbered sources drawn from the shared [references list](/references). The comparison page lines all three up on the dimensions that matter: mechanism, evidence base, administration route, regulatory status, and the single most important caveat for each. The aim is a quiet, accurate map of what is known — and where the map runs out. --- Peer-reviewed literature on the GH axis, summarized as a reading desk — not a vendor, not a clinic, and never a prescription.